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Abstract
Objective To compare validity including responsiveness,
andinternalconsistencyreliabilityandscalingassumptionsof
ageneric(SF-36)andParkinsonDisease(PD)-targeted(PDQ-
39; PDQUALIF) health-related quality of life (HRQOL)
measures.
Methods Ninety-six PD patients were administered for all
HRQOL measures by telephonic interview at baseline and
18 months. Relative efﬁciency and responsiveness were
compared relative to four external criteria (self-ratings of
PD’s daily effects, global Quality of Life, PD symptom
severity, and a depression screener). We examined whether
PD-targeted measures explained unique variance beyond
the SF-36 by regressing criterion variables on HRQOL
scales/items. Adequacy of PD-targeted measures’ original
scaling was explored by item-scale correlations.
Results Relative efﬁciency estimates were similar for gen-
eric and PD-targeted measures across all criteria. Respon-
siveness analyses showed that the SF-36 yielded large ([0.8)
effect sizes (ES) for three of eight scales for each of two
criterion variables, compared to only one large ES for any
scale in either PD-targeted measure. Adjusted R
2 increased
from 14 to 27% in regression models that included PD-
targeted items compared to models with only SF-36 scales.
Item-scale correlations showed signiﬁcant cross-loading of
items across scales of the PD-targeted measures.
Conclusions SF-36 responsiveness was better than that of
two PD-targeted measures, yet those measures had content
that signiﬁcantly explains PD patients’ HRQOL.
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Introduction
Parkinson’s disease (PD) is the second most prevalent neu-
rodegenerativediseaseafterAlzheimer’sdisease.PDafﬂicts
about one million Americans, or about 1% of the population
over 60 years of age [1]. As a chronic and progressive dis-
ease, PD may impact a person’s physical, mental and social
health. PD patients may experience impairments in mood
(especially depression and anxiety), orthostatic hypotension
and other autonomic symptoms, sleep disturbances, and
impulse control disorders, indicating the likelihood of a
broad impact of this disease on health [2, 3].
Health-related quality of life (HRQOL) conceptualizes
how well an individual functions and feels about his/her
life. It encompasses physical, mental, and social dimensions
of health [4]. There are two main types of HRQOL mea-
sures: generic and disease-targeted instruments, which dif-
fer in their form, content, and intended purpose. Generic
HRQOL measures enable comparisons across populations,
regardless of whether they have a particular condition [5].
The 36-Item Short-Form Health Survey (SF-36) is the most
widely used HRQOL survey instrument in the United States
[5, 6]. Its reliability and construct validity have been sup-
ported in studies of a number of other patient populations.
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most affected by disease and treatment, selected from 40
concepts assessed in the Medical Outcome Study [6].
Disease-targeted measures for several neurological
conditions, such as multiple sclerosis and epilepsy, may
provide additional key content over generic measures,
tapping domains of HRQOL important to persons with
these conditions [7, 8]. The most widely used PD-targeted
HRQOL measure is the Parkinson’s Disease Questionnaire
(PDQ-39), developed ﬁrst as a 65-item questionnaire
piloted on 359 individuals with PD attending a neurology
outpatient clinic [9]. After testing for basic acceptability
and comprehension, the number of questionnaire items was
reduced to 39 items by a factor analysis, distributed across
eight scales. The PDQ-39 has proved to have satisfactory
reliability and construct validity in relation to other mea-
sures but limited evidence of responsiveness [10].
Another PD-targeted HRQOL measure, the Parkinson’s
Disease Quality of Life (PDQUALIF) scale, was initially
developed and evaluated in a cross-sectional study of 233
outpatient clinic attendees with physician-conﬁrmed idio-
pathic PD [11]. Movement disorder specialists ranked a list
of 73 indicators relevant for quality of life (QOL) in PD, and
the top 32 ranked indicators were included in the measure.
More than any other PD-targeted measure, the PDQUALIF
taps many non-motor symptoms of PD including fatigue,
sleep, autonomic dysfunction, and sexual function.
Patient-reported outcome measures are increasingly
recognized as important for longitudinal studies including
clinical trials of new treatments (http://www.fda.gov/fdac/
features/2006/606_patients.html), and a review of a range
of disease-targeted measures found overall better ability to
detect change in clinically relevant domains relative to
generic measures [12]. Yet, disease-targeted measures
require investment of resources to develop and evaluate
relative to ‘‘off-the-shelf’’ existing generic measures in
widespread use, such as the SF-36. Thus, it is critical to
compare generic and disease-targeted measures on their
responsiveness to change in HRQOL over time. To date,
responsiveness indices (effect sizes) have been reported
only for the eight scales of the PDQ-39 scales, and in that
study, only a few scales detected any effect [10].
Our goals were to compare these two PD-targeted
HRQOL measures with the widely used SF-36 on respon-
siveness, construct validity, internal consistency reliability,
and scaling assumptions. Because the PDQ-39 is the most
widely used PD-targeted HRQOL measure, and because
the PDQUALIF was speciﬁcally intended to tap not only
motor but also non-motor aspects of QOL in PD, we
selected for inclusion these two PD-targeted measures out
of the small group of existing PD-targeted measures at the
time the study began [13]. We hypothesized that reliability
would be comparable but that the PD-targeted measures
would have better construct validity and responsiveness
than the generic SF-36.
Methods
Sample
A convenience sample of patients who were 18 years old
or older and English-speaking were recruited from the
Greater Los Angeles VA Healthcare System Movement
Disorders Clinic and from the University of California Los
Angeles (UCLA) Movement Disorders Clinic. At UCLA,
study ﬂyers were handed to PD patients by their movement
disorder physician at the time of the patient’s visit. At the
time of check-out from a regular appointment in the VA
Movement Disorders Clinic, patients with PD were
informed of the study and offered the ﬂyer. Recruiting
clinicians and staff were asked to provide information
about the study only to patients without diagnosed
dementia. In both sites, the ﬂyer contained information on
how to contact the study team through a toll-free telephone
number. If the patient expressed interest during the time of
check-out, the clinic clerk requested approval from the
patient for the research team to initiate contact with the
patient. Ninety-six patients provided verbal informed
consent and were enrolled and completed the baseline
telephone interview. The study was approved by the
Institutional Review Boards at the VA Greater Los Angeles
Healthcare System (project number PD1-01-158-1), and at
UCLA (approval number G050405204).
Study design
The baseline telephone interview took place between
March 2005 and February 2006, and the follow up inter-
view between December 2006 and March 2007. The
interval from baseline-to-follow up telephone interview
had a mean of 17.9 months (range equals 11.1–24 months),
a median of 17.9 months, and a standard deviation of
4.2 months. Measures were administered in the same way
at both baseline and follow-up to avoid differential effects
due to mode of administration [14].
Measures
Generic-HRQOL measure
The SF-36 (version 1.0) has 36 items covering eight scales:
Physical Functioning, Role Limitations due to Physical
Health, Role Limitations due to Emotional Problems, Pain,
Emotional Well-Being, Energy, General Health, and Social
Functioning. A Physical Health Composite score (PCS)
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derived from the SF-36 scales. The SF-36 is most com-
monly self-administered by mail survey or administered by
telephone interview [15, 16].
PD-targeted HRQOL measures
The PDQ-39 has 39 items covering eight scales: Mobility,
Activities of Daily Life, Emotional Well-Being, Stigma,
Social Support, Cognitions, Communication, and Bodily
Discomfort [9]. An overall score is constructed as the
average of the eight scale scores. The PDQ-39 has been
administered by telephone, with comparable levels of
missingness, reliability, and construct validity to self-
administration [3]. The PDQUALIF has 33 items covering
seven scales; Social and Role Function; Self Image and
Sexuality; Sleep; Outlook; Physical Functioning, Inde-
pendence; and Urinary Function [11]. An overall score is
the average of the seven scale scores.
In this study, all the PD-targeted HRQOL scales were
scored on a 0–100 possible range with 0 representing the
worst possible score and 100 the best possible score.
Criterion variables for evaluating validity of HRQOL
measures
We used four criterion variables to assess validity of the
HRQOL measures.
Criterion variable #1: ‘‘How PD affects you on a day-to-
day basis?’’ This single item global rating of difﬁculty with
day-to-day activities was developed speciﬁcally for PD
based on interviews with PD specialist clinicians, patients,
caregivers, and on a literature review; it has support for
construct validity in terms of anticipated associations with
depression, cognition, and PD severity in a community-
based PD sample [17]. Subjects are asked to indicate one
choice that ‘‘best describes how your Parkinson’s disease
has affected your day-to-day activities in the last month:’’
(1) no difﬁculties, (2) mild difﬁculties, (3) moderate difﬁ-
culties, (4) high levels of difﬁculties, or (5) extreme difﬁ-
culties. Each choice is followed by a detailed example.
Criterion variable #2: ‘‘Current rating of overall QOL on
scale of 1 to 10.’’ Subjects chose an integer between 1
(worst possible QOL, as bad as or worse than being dead)
and 10 (the best possible QOL). This variable was adapted
from other measures [18].
Criterion variable #3: ‘‘Rating of PD symptoms in the
past 6 months’’. In order to assess symptom severity,
subjects were asked to rate the severity of their symptoms
as (1) no symptoms, (2) mild symptoms, (3) moderate
symptoms, and (4) severe symptoms.
Criterion variable #4: ‘‘Patient Health Questionnaire
(PHQ)-9 Scoring Categories’’. This nine-item self-rated
depression screener is directly mapped on the Diagnostic
and Statistical Manual-IV (DSM-IV) criteria for major
depression [19]. It has been evaluated in large studies of
primary care patients and used in a recent large trial of
depression care in the elderly [20]. Three categories can be
derived based on responses to the nine items: (1) depres-
sion treatment may be not needed, (2) clinical judgments
about treatment on duration of symptoms and functional
impairments, and (3) warrants treatment for depression.
We hypothesized that the PD-targeted HRQOL measures
would be more highly associated than the SF-36 with the
two criterion variables that elicited ratings of day-to-day
difﬁcultieswithPD(criterionvariable#1)andPDsymptoms
(criterion variable #3). Because the two PD-targeted
HRQOL measures each had one summary score and the
SF-36 had separate physical and mental health composite
scores, we hypothesized that the SF-36 mental health com-
posite score would be more highly associated with the PHQ-
9 (criterion variable #4) than all the three other summary
scores. We had no a priori hypotheses with respect to the
global QOL rating (criterion variable #2) and summary
scores of PD-targeted versus generic measures, nor did we
make any formal a priori hypotheses about individual scale
scores on any measure and the four criterion variables.
Socio-demographic and clinical characteristics included
gender, age, race/ethnicity, marital status, education, and
employment. We also collected self-reported Activities of
Daily Living (ADL) via the Uniﬁed Parkinson’s Disease
Rating Scale (UPDRS) [21].
Data collection
Telephone interviews were administered by trained
research assistants who followed protocols for quality of
data collection by interview. Participants were paid $10 for
each interview. The research assistant obtained verbal
consent over the telephone. Data were directly entered into
an electronic spreadsheet. Reasons for the 38 non-respon-
dents (39.6% non-response) at the follow-up interview
1–2 years later include: unreachable despite multiple
attempts by phone (n = 19), phone number disconnected
(n = 6), asked to not be contacted again after the ﬁrst
survey (n = 4), declined (n = 4), unable to participate
because of stroke/dementia (n = 3), deceased (n = 1), and
other (n = 1).
Data analysis
Data were analyzed using SAS version 9.1 (SAS
 soft-
ware, Version 9.1, SAS Institute, Cary, NC).
Mean scores, standard deviations, ranges, and percent-
ages of patients scoring the minimum = 0 (ﬂoor), and
maximum = 100 (ceiling) possible scores were examined.
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assessed using Cronbach’s alpha [22]. Reliability of com-
posite scores was estimated using Mosier’s formula [23].
We categorized scales as reliable if Cronbach’s alpha was
greater than or equal to 0.70, a widely used threshold for
adequate reliability in group comparisons [24, 25].
Relative validity is reported as the ratio of the F-statistic
of each scale of the three HRQOL measures to the F-
statistic of a designated reference scale, usually the
smallest F-statistic among the scales of the three HRQOL
measures [26]. For a given criterion variable, the scale with
the highest F-ratio is thus most sensitive to differences
across categories of that criterion variable; for a ﬁxed level
of power, relative validity (F-ratio) values ‘‘are equivalent
to the ratio of sample sizes that would be required to detect
the known group difference using one measure versus the
other’’ [27]. For each of the four criterion variables
(baseline distributions in Table 1 and Appendix Table 7),
we used analysis of variance (ANOVA) based F-statistics
to compare mean HRQOL scale scores across different
patient groups, based on patient’s categorization across
different levels within that criterion variable [27].
Responsiveness was assessed using standard methods
[28]. We examined the decline in responses between the
baseline and the follow-up interviews for criterion variable
#1 (‘‘How PD affects you on a day-to-day basis’’) and for
criterion variable #2 (‘‘Current rating of overall QOL’’).
We excluded responses from subjects who ‘‘improved’’
rather than combining them with ‘‘declined’’ because prior
studies suggest that the magnitude of responsiveness is
different for these two groups and higher among
‘‘declined’’ [29], and PD is a disease of progressive decline
[29]. We examined the distribution of the change in
responses and used the existing literature and clinical
judgment to set the threshold for a change in each criterion
variable. For criterion variable #1 of how PD affects you
daily, each of the ﬁve response choices were developed as
clinically distinct and meaningful [17]; thus, we set a
threshold of true change to be a change of at least one level.
For criterion variable #2 of overall QOL, there are 10
response choices with anchors only at each extreme; we set
a threshold of true change to be at least two levels based on
our judgment. Selection of these thresholds was made
a priori. Unchanged was deﬁned as responses on the second
interview that did not meet threshold for a true change from
the ﬁrst interview. The three most widely used respon-
siveness indices were calculated: effect size (ES), stan-
dardized response mean (SRM), and the Guyatt
responsiveness statistic (GRS) [30]. For these indices, the
numerator is the mean change in scale score for the
declined group. The denominators are the standard devia-
tion of the baseline scale score of the declined group (ES),
the standard deviation of change in scale score for the
change group (SRM), and the standard deviation of change
in scale score for the unchanged group (GRS) [27].
Because each of these indices look at change for the
declined group, we supplemented them by computing the
F-statistic for the difference in change scores between the
declined and unchanged groups. We categorized ES as
large (greater than or equal to 0.80), medium (between 0.50
and 0.79), small (between 0.20 and 0.49), and not detect-
able (less than 0.2) according to well-known published
benchmarks [31] and focused on ES in our interpretation,
because such established benchmarks exist. (There is one
published report providing regression equations linking
different responsiveness indices [32].)
We used multivariate models to determine whether PD-
targeted measures captured important HRQOL content
beyond the SF-36. Each of the four criterion variable
served as the dependent variable in a multivariate model,
and the eight SF-36 scales served as the independent
variables (Model 1). We then forced in the SF-36 scales
that were signiﬁcant at P\0.10 in Model 1 and allowed
items from the two PD-targeted HRQOL measures to enter
at P\0.05 (Model 2), using stepwise regression. We
compared the improvement in adjusted R
2 from Model 1 to
Model 2 for each of the criterion variables.
In order to evaluate the original scoring of the two-PD
targeted measures,weestimatedusingbaselinedatafromall
the 96 subjects, the item-scale correlations from multitrait
scaling analyses [33]; computing product-moment correla-
tions between items and scales, correcting for the overlap of
the item with the scale where applicable. We inspected the
correlation matrix for potential lack of item discrimination
across scales by highlighting those correlations that were 
standard error below or any amount above the correlation of
the item with the scale in which it was placed.
Results
Sample characteristics
The mean age of the 96 enrolled PD patients was 72 years,
88% were white. More than three-quarters (84%) were
male (see Table 1). Sixty-ﬁve percent were currently
married; 63% held a Bachelor’s degree or higher; 66%
were retired and not working, and 58% reported moderate
or severe PD symptoms.
For criterion variable #1 (How PD affects you on a day-
to-day basis), 54% reported moderate, high, or extreme
difﬁculties. For criterion variable #2 (rating of overall
QOL), 61% rated their QOL as 7 or higher on the 1–10
QOL scale.
We compared characteristics of the 58 participants who
completed the follow up interview to the 38 who did not
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Total Patients with follow-up data Patients without follow-up data
a P-value
N (%)
Mean (SD)
N = 96
N (%)
Mean (SD)
N = 58
N (%)
Mean (SD)
N = 38
Male 81 (84.4) 46 (79.3) 35 (92.1) 0.09
Age 71.6 (10.9) 70.9 (10.2) 72.6 (11.9) 0.44
Race
White 84 (87.5) 53 (91.4) 31 (81.6) 0.03
Black 3 (3.1) 3 (5.2) 0 (0.0)
Hispanic 7 (7.3) 1 (1.7) 6 (15.8)
Asian 1 (1.0) 0 (0.0) 1 (2.6)
Other 1 (1.0) 1 (1.7) 0 (0.0)
Marital status
Married 62 (64.6) 35 (60.3) 27 (71.1) 0.34
Separated 2 (2.1) 1 (1.7) 1 (2.6)
Divorced 18 (18.8) 14 (21.1) 4 (10.5)
Widowed 9 (9.4) 4 (6.9) 5 (13.2)
Never married 5 (5.2) 4 (6.9) 1 (2.6)
Highest degree
None/less than high school 3 (3.1) 2 (3.5) 1 (2.6) 0.78
High school or GED 22 (22.9) 11 (19.0) 11 (29.0)
Associate’s degree 11 (11.5) 8 (13.8) 3 (8.0)
Bachelor’s degree 38 (39.6) 23 (39.7) 15 (39.5)
Graduate/professional degree 22 (22.9) 14 (24.1) 8 (21.1)
Years of schooling 15.7 (2.4) 15.7 (2.5) 15.5 (2.3) 0.68
Employment
Working full time/part time 18 (18.8) 6 (10.3) 12 (31.6) 0.06
With a job and not working for other reasons 1 (1.0) 1 (1.7) 0 (0.0)
Unemployed and looking for work 1 (1.0) 0 (0.0) 1 (2.6)
Disabled and not working 13 (13.5) 9 (15.5) 4 (10.5)
Retired and not working 63 (65.6) 42 (72.4) 21 (55.3)
UPDRS ADLs scale
(Range: 0–48) 0 = best state 14.5 (7.6) 14.2 (7.8) 15.1 (7.3) 0.54
Recruited at VA 54 (56.2) 32 (55.2) 22 (57.9) 0.79
How Parkinson’s disease affects you on a day-to-day basis?
No difﬁculties 10 (10.4) 8 (13.8) 2 (5.3) 0.17
Mild difﬁculties 34 (35.4) 23 (39.7) 11 (28.9)
Moderate difﬁculties 38 (39.6) 17 (29.3) 21 (55.3)
High levels of difﬁculties 12 (12.5) 10 (17.2) 2 (5.3)
Extreme difﬁculties 2 (2.1) 0 (0.0) 2 (5.3)
On a scale of 1–10, where 10 is the best possible quality of life and 1 is the worst possible quality of life (as bad or worse than being dead)
overall, how would you rate your quality of life?
1 1 (1.0) 1 (1.7) 0 (0.0) 0.33
2 1 (1.0) 0 (0.0) 1 (2.6)
3 4 (4.2) 1 (1.7) 3 (7.9)
4 5 (5.2) 3 (5.2) 2 (5.3)
5 15 (15.6) 11 (19.0) 4 (10.5)
6 11 (11.5) 5 (8.6) 6 (15.8)
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niﬁcant difference was ethnicity, with a higher proportion
of white participants in the follow up.
Descriptive statistics and reliability
There were noteworthy ﬂoor effects for the SF-36 Role
Limitations—Physical scale (51% of sample scored the
possible minimum) and ceiling effects for the SF-36 Role
Limitations—Emotional scale (75% of the sample scored
the possible maximum, see Table 2). On the PDQ-39, there
was a ceiling effect for the Social Support scale (54% of
the sample scored the possible maximum). On the
PDQUALIF, there was substantial ceiling effects for the
Independence scale (60% of the sample scored the possible
maximum).
Internal consistency reliability was satisfactory for all
the eight SF-36 scales (Cronbach’s alpha[0.70). How-
ever, coefﬁcient alpha for three of the seven PDQUALIF
scales (Physical Function, Outlook, and Sleep scales) fell
below the 0.70 threshold for adequate reliability to make
group comparisons (ranging from 0.52 to 0.60). Likewise,
alphas for two of eight PDQ-39 scales (Cognition and
Bodily Discomfort scales) were 0.59 and 0.68.
Relative validity
Criterion variable #1: how PD affects you on a day-to-day
basis
Ten patients had no difﬁculties, 34 reported mild difﬁcul-
ties, 38 patients had moderate difﬁculties and 14 patients
had high levels or extreme difﬁculties (see Table 3). The
PDQUALIF Social/Role Function scale and the PDQ-39
Mobility scale had the highest relative validity (13.3 and
11.7). The level of discrimination across the four categories
of the criterion variable was higher for the overall score of
the two PD-targeted measures (relative validity = 9.3 for
the PDQUALIF, and 10.6 for the PDQ-39) compared to
either composite score of the SF-36 (relative validity = 5.5
for SF-36 PCS, 2.9 for SF-36 MCS).
Criterion variable #2: rating of overall QOL
Twenty-eight patients who rated their overall QOL as 8, 9,
or 10 were combined into one group, 42 patients whose
ratings were 6 or 7 were combined into another group, and
26 patients whose ratings were 1–5 were combined into a
third group (see Table 4). The highest relative validity was
observed for the SF-36 Emotional Well Being scale (rela-
tive validity = 15.44). The SF-36 MCS had higher relative
validity than the overall scores of the two PD-targeted
HRQOL measures.
Similarly, for the other two criterion variables, the
overall scores of the two PD-targeted measures did not
perform appreciably better than the SF-36 PCS and MCS.
(See Appendix Tables 8 and 9 for details.)
Responsiveness of HRQOL measures
For criterion variable #1 (‘‘How PD affects you on a day-
to-day basis’’), 20 patients reported at least one level of
worsening on the second interview and were categorized as
‘‘declined’’ and 23 patients were categorized as ‘‘unchan-
ged.’’ The highest ES for any overall or composite score
was for the SF-36 PCS (ES =- 0.86), corresponding to a
large ES (see Table 5).
For criterion variable #2 (rating of overall QOL), 16
patients reported at least two levels of worsening on the
second interview and were categorized as ‘‘declined’’
versus 35 patients who rated within one point of baseline
and were categorized as ‘‘unchanged’’ (see Table 6). The
SF-36 MCS (ES =- 1.06) had the highest ES, again cor-
responding to a large ES.
We found three of the eight SF-36 scales had a large ES
for each criterion variable examined. In contrast, only the
Table 1 continued
Total Patients with follow-up data Patients without follow-up data
a P-value
N (%)
Mean (SD)
N = 96
N (%)
Mean (SD)
N = 58
N (%)
Mean (SD)
N = 38
7 31 (32.3) 18 (31.0) 13 (34.2)
8 21 (21.9) 13 (22.4) 8 (21.1)
9 6 (6.3) 5 (8.6) 1 (2.6)
10 1 (1.0) 1 (1.7) 0 (0.0)
a Mean number of months between baseline and follow up survey is 17.9 (SD = 4.2; range = 11.1–24.0 months; IQR = 13.6–22.1 months).
Two-sample t-test was used for age and years of schooling. Chi-square test was used for gender, race, marital status, highest degree, employment,
and recruited at VA. Wilcoxon rank-sum test was used for all others
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the criterion variable on PD’s day-to-day effects; the ES
for the other six PDQUALIF and eight PDQ-39 scales were
not as large for either criterion variable.
Contributions of PD-targeted and generic HRQOL
content to explaining criterion variables
Using criterion variable #1 (PD’s day-to-day effects) as
the dependent variable, the following three SF-36 scales
entered the multivariate model at P\0.10: Social
Functioning, Physical Functioning, and Role Limita-
tions—Physical (Model 1). In Model 2, the following
three PDQUALIF items from the PD-targeted measures
entered the model at P\0.05 after forcing in the
above three SF-36 scales: Financial strain (Self-Image/
Sexuality scale), Adjust to change (Social Role Func-
tion scale), Sleep with partner (Sleep scale); the fol-
lowing two PDQ-39 items also entered: Getting around
house (Mobility scale) and Memory (Cognition scale).
The adjusted R
2 i m p r o v e df r o m0 . 4 8i nM o d e l1t o0 . 6 5
in Model 2.
Table 2 Descriptive statistics and reliability of HRQOL scales (N = 96)
a
Baseline Number of items Mean SD Percent scoring minimum
(= 0)/maximum (= 100)
Cronbach’s
alpha
SF-36 v. 1.0 (range: 0–100, where 100 is best quality of life)
Physical Function 10 58.0 30.8 4.2/3.1 0.94
Role Limitations—Physical 4 28.4 35.3 51.0/10.4 0.81
Role Limitations—Emotional 3 76.4 41.9 21.9/75.0 0.98
Pain 2 63.2 26.5 0.0/15.6 0.85
Emotional Well-Being 5 69.7 18.1 1.0/0.0 0.86
Energy 4 47.0 22.8 3.1/0.0 0.92
General Health 5 52.4 22.0 2.1/1.0 0.76
Social Function 2 61.0 33.3 6.3/29.2 0.98
SF-36 composite scores (T-scores)
Physical Health (PCS) – 36.0 10.5 n/a 0.93
b
Mental Health (MCS) – 49.1 12.0 n/a 0.97
b
PDQUALIF (range: 0–100, where 100 is best quality of life)
Social/Role Function 9 52.6 26.0 1.0/1.0 0.88
Self-Image and Sexuality 7 60.3 23.4 0.0/4.2 0.80
Sleep 3 64.6 28.3 2.1/21.1 0.60
Outlook 4 61.1 21.3 0.0/3.2 0.55
Physical Function 5 70.9 17.4 0.0/2.1 0.52
Independence 2 79.2 32.9 11.6/60.0 0.89
Urinary Function 2 39.3 35.4 27.4/10.5 0.85
Total score – 61.2 18.4 – 0.93
b
PDQ-39 (range: 0–100, where 100 is best quality of life)
Mobility 10 62.2 29.3 2.1/5.2 0.93
Activities of Daily Living 6 65.3 25.0 2.1/5.2 0.89
Emotional Well-Being 6 74.3 21.5 1.0/9.4 0.86
Stigma 4 74.6 28.2 1.0/34.4 0.88
Social Support 3 83.2 25.9 2.1/54.2 0.85
Cognitions 4 73.4 20.4 1.0/10.4 0.68
Communication 3 75.8 23.4 1.0/29.2 0.75
Bodily Discomfort 3 62.2 22.7 1.0/7.3 0.59
Total score – 71.4 18.0 – 0.96
b
a All the scales scored on a 0 (worst) to 100 (best) possible range, except for the SF-36 PCS and MCS, which are T-scores (mean = 50,
SD = 10) calculated against a reference population
b Calculated using Mosier’s formula
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following four SF-36 scales entered the model at P\0.10:
Role Limitations—Physical, General Health, Role Limi-
tations—Emotional, and Emotional Well-Being (Model 1).
Then in Model 2, the following three PDQUALIF items
from the PD-targeted measures entered at P\0.05 after
forcing in to the above four SF-36 scales: Sexual ability
(Self-image/Sexuality scale), Future and Ask for help (both
from the Outlook scale), and Independent hygiene (Inde-
pendence scale); the following three PDQ-39 items also
entered: Conﬁned to the house (Mobility scale), Isolated
and lonely (Emotional/Well-Being scale), and Concentra-
tion (Cognition scale). The adjusted R
2 improved from 0.45
in Model 1 to 0.65 in Model 2. (See Appendix Table 10 for
stepwise results for these two criterion variables and also
for criterion variables # 3 and # 4.)
Table 3 Relative validity of HRQOL scales by how PD affects on day-to-day basis rating (N = 96)
a
How Parkinson’s disease affects you on a day-to-day basis?
Scale No difﬁculties
(n = 10)
Mild difﬁculties
(n = 34)
Moderate difﬁculties
(n = 38)
High levels of or extreme
difﬁculties (n = 14)
F-ratio
b Relative
validity
c
SF-36 v. 1.0 (range: 0–100, where 100 is best quality of life)
Physical Function 88.5
d 71.6
d 48.2
e 29.6
f 15.72 6.72
Role Limitations—Physical 67.5
d 41.9
e 16.5
f 0.0
f 14.64 6.26
Role Limitations—Emotional 90.0
d 88.2
d 7.6
d 42.9
e 4.79 2.05
Pain 77.5
d 64.9
d 67.5
d 37.1
e 6.97 2.98
Emotional Well-Being 76.4
d 76.9
d 67.6
d 53.1
e 7.66 3.27
Energy 69.5
d 56.0
e 39.2
f 30.4
f 12.14 5.19
General Health 64.5
d 57.9
d,e 47.9
e,f 42.5
f 3.44 1.47
Social Function 88.8
d 79.4
d 49.7
e 26.8
f 19.13 8.18
SF-36 composite scores (T-scores)
Physical Health (PCS) 47.7
d 39.2
e 33.2
e 27.1
f 12.86 5.50
Mental Health (MCS) 53.4
d 53.4
d 47.3
d 39.2
e 6.68 2.85
PDQUALIF (range: 0–100, where 100 is best quality of life)
Social/Role Function 80.8
d 67.5
e 42.5
f 21.4
g 31.07 13.28
Self-Image and Sexuality 82.1
d 71.1
d 53.3
e 35.9
f 16.71 7.14
Sleep 85.0
d 70.6
d,e 57.2
e 54.5
e 4.00 1.71
Outlook 75.0
d 71.9
d 53.3
e 44.7
e 11.44 4.89
Physical Function 83.5
d 75.3
d,e 69.7
e 53.5
f 8.49 3.63
Independence 100.0
d 87.7
d 79.9
d 38.5
e 11.84 5.06
Urinary Function 55.0
d 47.1
d,e 29.3
e 36.5
d,e 2.34
c 1.00
Total score 80.2
d 70.2
e 55.0
f 40.7
g 21.64 9.25
PDQ-39 (range: 0–100, where 100 is best quality of life)
Mobility 94.0
d 77.8
e 52.4
f 28.0
g 27.4 11.71
Activities of Daily Living 88.8
d 75.1
d 60.2
e 38.4
f 15.43 6.59
Emotional Well-Being 85.4
d 85.2
d 67.3
e 58.6
e 9.63 4.12
Stigma 81.9
d 86.0
d 72.2
d 48.2
e 7.57 3.24
Social Support 91.7
d 93.6
d 79.6
d 61.9
e 6.58 2.81
Cognitions 81.3
d 80.3
d 69.6
d, e 61.2
e 4.34 1.85
Communication 91.2
d 86.6
d 68.4
e 56.6
e 11.95 5.11
Bodily Discomfort 74.2
d 69.4
d 59.4
d 43.5
e 6.33 2.71
Total score 86.4
d 81.8
d 66.2
e 49.5
e 24.8 10.60
a All the scales scored on a 0 (worst) to 100 (best) possible range, except for the SF-36 PCS and MCS, which are T-scores (mean = 50,
SD = 10) calculated against a reference population
b One way between group ANOVAs of HRQOL scale and day-to-day effects of PD
c Reference scale = PDQUALIF—Urinary Function (F-ratio = 2.34)
d, e, f, g Means within a row with different letters differ signiﬁcantly (P\0.05; Duncan multiple range)
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Item-scale correlations using baseline data from the sample
of 96 enrollees revealed that 18 of 32 PDQUALIF items
correlated within 0.05 (one-half the standard error in this
dataset) below or correlated more highly with other scales
than the scales they were supposed to represent. Particu-
larly problematic were the Outlook and Physical Func-
tioning scales: three out of four Outlook scale items
correlated more highly on another scale than Outlook, and
all the ﬁve Physical Functioning items correlated more
highly with another scale than the Physical Functioning
scale (see Appendix Table 11).
Item-scale correlations for ﬁve of the eight PDQ-39
scales in general provided support for the arrangement of
items by scale using our criteria for item discrimination
across scales. However, all three items from the Bodily
Discomfort scale, two out of the four items from the
Table 4 Relative validity of HRQOL scales by quality of life rating (N = 96)
a
Scale On a scale of 1–10, where 10 is best possible quality of life and 1 is the worst possible quality of life (as bad or
worse than being dead) overall, how would you rate your quality of life?
Values 8–10
(n = 28)
Values 6–7
(n = 42)
Values 1–5
(n = 26)
F-ratio
b Relative
validity
c
SF-36 v. 1.0 (range: 0–100, where 100 is best quality of life)
Physical Function 71.8
d 58.2
d 42.7
e 6.74 3.46
Role Limitations—Physical 50.9
d 26.8
e 6.7
f 13.42 6.88
Role Limitations—Emotional 100.0
d 83.3
d 39.7
e 21.45 11.00
Pain 73.6
d 63.5
d,e 51.5
e 5.06 2.59
Emotional Well-Being 80.7
d 73.4
e 51.9
f 30.10 15.44
Energy 62.9
d 45.1
e 33.1
f 15.29 7.84
General Health 65.4
d 52.9
e 37.7
f 13.42 6.88
Social Function 82.1
d 62.5
e 35.6
f 18.00 9.23
SF-36 composite scores (T-scores)
Physical Health (PCS) 41.3
d 35.0
e 31.8
e 6.47 3.32
Mental Health (MCS) 56.7
d 51.0
e 37.7
f 28.05 14.38
PDQUALIF (range: 0–100, where 100 is best quality of life)
Social/Role Function 67.8
d 52.8
e 35.2
f 13.04 6.69
Self-Image and Sexuality 74.6
d 59.6
e 45.6
f 12.75 6.54
Sleep 76.2
d 64.9
e 51.0
e 5.77 2.96
Outlook 72.3
d 64.1
d 43.3
e 17.73 9.09
Physical Function 80.4
d 68.7
e 64.2
e 7.13 3.66
Independence 86.6
d 80.4
d,e 69.0
e 1.95
c 1.00
Urinary Function 53.1
d 32.1
e 36.0
e 3.26 1.67
Total score 73.0
d 60.4
e 49.2
f 14.28 7.32
PDQ-39 (range: 0–100, where 100 is best quality of life)
Mobility 77.1
d 63.2
e 44.6
f 9.93 5.09
Activities of Daily Living 75.9
d 65.6
e 53.4
f 6.05 3.10
Emotional Well-Being 85.9
d 77.9
e 55.9
f 19.56 10.03
Stigma 86.4
d 77.1
e 57.9
f 8.25 4.23
Social Support 96.7
d 86.3
d 63.8
e 14.75 7.56
Cognitions 80.1
d 71.4
d,e 69.2
e 2.33 1.19
Communication 88.5
d 75.0
e 63.5
f 9.09 4.66
Bodily Discomfort 73.2
d 59.9
e 53.9
e 5.79 2.97
Total score 82.9
d 72.0
e 57.8
f 18.29 9.38
a All the scales scored on a 0 (worst) to 100 (best) possible range, except for the SF-36 PCS and MCS, which are T-scores (mean = 50,
SD = 10) calculated against a reference population
b One way between group ANOVAs of HRQOL scale and quality of life rating
c Reference scale = PDQUALIF—Independence (F-ratio = 1.95)
d, e, f Means within a row with different letters differ signiﬁcantly (P\0.05; Duncan multiple range)
Qual Life Res (2009) 18:1219–1237 1227
123Cognition scale, and one out of the three items from the
Communication scale loaded similarly or more highly on
other scales than on the scale in which they are placed (see
Appendix Table 12).
Discussion
We analyzed and compared the psychometric properties of
a widely used generic measure of HRQOL, the SF-36, and
two PD-targeted measures, the PDQ-39 and the PDQUA-
LIF measures. While relative validity was somewhat better
for the PD-targeted measures than the SF-36 on criterion
variables that asked speciﬁcally about activities limited by
PD or about PD symptoms, we found greater support for
the responsiveness of the SF-36 than for the PD-targeted
measures on both external criterion variables, including the
variable on difﬁculties in day-to-day activities due to PD.
Despite better responsiveness of the generic measure,
however, multivariate regression models showed that items
Table 5 Responsiveness indices: declined and unchanged groups based on ‘‘How Parkinson’s disease affects you on a day-to-day basis?’’
a
Baseline mean in
declined group (SD)
Average change in
declined group (SD)
Average change in the
unchanged group (SD)
Effect size
statistic
SRM Guyatt F (P value)
SF-36 v. 1.0 (range: 0–100, where 100 is best quality of life)
Physical Function 70.0 (26.7) -22.8 (22.0) -1.6 (22.9) -0.85
b -1.04 -0.99 9.54 (0.004)
Role Limitations—Physical 47.5 (41.3) -16.3 (43.9) 6.9 (29.4) -0.39
d -0.37 -0.55 4.22 (0.05)
Role Limitations—
Emotional
90.0 (30.8) -11.7 (49.9) -2.9 (43.7) -0.38
d -0.23 -0.27 0.38 (0.54)
Pain 68.4 (24.5) -1.5 (30.0) 2.2 (26.5) -0.06 -0.05 -0.06 0.18 (0.67)
Emotional Well-Being 77.8 (13.8) -1.2 (19.0) -3.0 (18.9) -0.09 -0.06 -0.06 0.09 (0.76)
Energy 66.3 (17.2) -19.5 (22.3) -3.0 (23.7) -1.13
b -0.87 -0.82 5.44 (0.03)
General Health 69.8 (10.4) -18.0 (17.7) -4.1 (13.8) -1.72
b -1.02 -1.31 8.31 (0.006)
Social Function 81.9 (24.5) -12.5 (39.5) 1.1 (28.2) -0.51
c -0.32 -0.44 1.72 (0.20)
SF-36 composite scores (T-scores)
Physical Health (PCS) 41.3 (8.9) -7.7 (10.1) 0.8 (6.9) -0.86
b -0.76 -1.11 10.51 (0.002)
Mental Health (MCS) 55.5 (8.5) -2.5 (10.7) -1.6 (10.8) -0.29
d -0.23 -0.22 0.08 (0.78)
PDQUALIF (range: 0–100, where 100 is best quality of life)
Social/Role Function 69.4 (23.9) -19.1 (21.7) -1.7 (21.1) -0.80
b -0.88 -0.91 6.98 (0.01)
Self-Image and Sexuality 69.5 (22.9) -5.9 (19.6) 7.8 (19.3) -0.26
d -0.30 -0.31 5.18 (0.03)
Sleep 72.5 (29.0) -10.0 (23.8) -12.8 (28.9) -0.35
d -0.42 -0.35 0.12 (0.73)
Outlook 74.7 (18.3) -3.8 (18.5) 1.4 (19.1) -0.21
d -0.21 -0.20 0.79 (0.38)
Physical Function 73.0 (19.9) -3.3 (19.7) -11.1 (13.5) -0.16 -0.17 -0.24 2.32 (0.14)
Independence 84.4 (31.9) -20.6 (34.5) -1.14 (32.0) -0.65
c -0.60 -0.64 3.61 (0.07)
Urinary Function 43.1 (31.0) 2.5 (36.9) 0.6 (44.4) -0.08 0.07 0.06 0.02 (0.88)
Total score 69.5 (17.2) -8.6 (15.2) -2.4 (17.7) -0.50
c -0.57 -0.49 1.44 (0.24)
PDQ-39 (range: 0–100, where 100 is best quality of life)
Mobility 75.4 (26.4) -16.9 (26.1) 5.4 (16.2) -0.64
c -0.65 -1.04 11.62 (0.002)
Activities of Daily Living 68.3 (27.5) -13.5 (27.1) 2.0 (15.1) -0.49
d -0.50 -0.89 5.59 (0.02)
Emotional Well-Being 85.0 (20.9) -7.1 (14.3) -1.5 (15.2) -0.34
d -0.49 -0.47 1.51 (0.23)
Stigma 80.9 (27.8) 4.7 (22.2) 10.9 (21.1) 0.17 0.21 0.22 0.88 (0.35)
Social Support 88.3 (27.1) 0.4 (34.0) 2.7 (18.2) 0.02 0.01 0.02 0.08 (0.78)
Cognitions 74.1 (17.4) -7.2 (21.8) -1.4 (12.9) -0.41
d -0.33 -0.56 1.18 (0.29)
Communication 83.1 (23.5) -14.2 (16.2) 2.2 (21.4) -0.60
c -0.88 -0.66 7.8 (0.008)
Bodily Discomfort 63.8 (25.6) -7.5 (23.6) 2.5 (20.6) -0.29
d -0.32 -0.36 2.22 (0.14)
Total score 77.4 (19.7) -7.7 (15.9) 2.9 (11.1) -0.39
d -0.48 -0.69 6.44 (0.02)
a Declined group declined at least one category from baseline to follow-up (n = 20); Unchanged group remained in the same category at follow-
up (n = 23). All the scales scored on a 0 (worst) to 100 (best) possible range, except for the SF-36 PCS and MCS, which are T-scores
(mean = 50, SD = 10) calculated against a reference population
b Large effect size (effect size greater than or equal to 0.80)
c Medium effect size (effect size between 0.20 and 0.49)
d Small effect size (effect size between 0.50 and 0.79)
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content not covered by the SF-36 scales. An analysis of the
PD-targeted measures revealed multiple problems with
items correlating as highly or more highly with other scales
than with the scale they were intended to represent,
potentially accounting for the unanticipated ﬁnding of
superior responsiveness of the SF-36 compared to the
PD-targeted measures.
Few studies have compared the psychometric proper-
ties of the SF-36 with a PD-targeted measure. The
responsiveness of the SF-36 and PDQ-39 was tested
among 132 PD patients by administering it at baseline
and at 4 months and asking a criterion question of
whether there was change in the effect of PD on
everyday life [10]. In that study, none of the PDQ-39
had a large ES, the PDQ-39 mobility scale showed a
Table 6 Responsiveness indices: declined and unchanged groups based on ‘‘On a scale of 1 to 10, where 10 is best possible quality of life and 1
is the worst possible quality of life (as bad or worse than being dead) overall, how would you rate your quality of life?’’
a
Baseline mean in
declined group (SD)
Average change in
declined group (SD)
Average change in the
unchanged group (SD)
Effect size
statistic
SRM Guyatt F (P value)
SF-36 v. 1.0 (range: 0–100, where 100 is best quality of life)
Physical Function 59.1 (29.2) -12.6 (23.9) -7.0 (24.3) -0.43
d -0.53 -0.52 0.58 (0.45)
Role Limitations—Physical 50.0 (44.7) -15.6 (49.1) 4.5 (33.5) -0.35
d -0.31 -0.47 2.94 (0.09)
Role Limitations—Emotional 93.8 (25.0) -12.5 (29.5) -7.6 (51.2) -0.50
c -0.42 -0.24 0.13 (0.72)
Pain 69.8 (23.3) -9.5 (32.8) 8.9 (29.7) -0.40
d -0.29 -0.32 3.95 (0.05)
Emotional Well-Being 80.5 (7.4) -6.0 (19.3) 0.9 (16.4) -0.81
b -0.31 -0.37 1.75 (0.19)
Energy 60.6 (20.4) -17.2 (24.2) -4.7 (24.7) -0.84
b -0.71 -0.70 2.84 (0.10)
General Health 66.9 (12.8) -15.9 (14.4) -4.7 (18.9) -1.24
b -1.10 -0.84 4.46 (0.04)
Social Function 83.6 (26.9) -19.5 (39.0) 6.4 (32.8) -0.72
c -0.50 -0.59 6.10 (0.02)
SF-36 composite scores (T-scores)
Physical Health (PCS) 38.7 (9.8) -5.7 (10.8) -0.1 (9.5) -0.58
c -0.52 -0.60 3.52 (0.07)
Mental Health (MCS) 57.3 (5.0) -5.3 (10.9) -0.3 (10.5) -1.06
b -0.49 -0.50 2.44 (0.13)
PDQUALIF (range: 0–100, where 100 is best quality of life)
Social/Role Function 67.2 (26.4) -18.4 (22.7) -1.6 (21.6) -0.70
c -0.81 -0.85 6.43 (0.02)
Self-Image and Sexuality 62.1 (25.4) -6.9 (19.0) 4.3 (19.1) -0.27
d -0.36 -0.39 3.78 (0.06)
Sleep 71.4 (30.3) -16.9 (25.9) -10.4 (27.9) -0.56
c -0.65 -0.61 0.63 (0.43)
Outlook 66.8 (19.9) 0.8 (11.8) 2.5 (10.1) 0.04 0.07 0.08 0.10 (0.75)
Physical Function 71.6 (21.7) -4.4 (17.5) -4.9 (16.6) -0.20
d -0.25 -0.27 0.01 (0.93)
Independence 84.4 (34.3) -18.0 (36.2) 6.4 (37.9) -0.52
c -0.50 -0.48 4.67 (0.04)
Urinary Function 43.0 (32.6) -5.5 (35.4) 1.1 (42.0) -0.17 -0.16 -0.13 0.29 (0.59)
Total score 66.6 (17.6) -9.9 (13.5) -0.4 (17.2) -0.56
c -0.73 -0.58 3.83 (0.06)
PDQ-39 (range: 0–100, where 100 is best quality of life)
Mobility 68.9 (27.4) -13.7 (26.1) 4.7 (22.8) -0.50
c -0.52 -0.60 6.59 (0.01)
Activities of Daily Living 64.8 (27.0) -10.7 (20.5) 1.8 (26.4) -0.40
d -0.52 -0.41 2.80 (0.10)
Emotional Well-Being 83.9 (18.3) -4.9 (8.8) -3.0 (17.1) -0.27
d -0.56 -0.29 0.18 (0.67)
Stigma 77.7 (24.4) 4.3 (18.9) 13.2 (21.5) 0.18 0.23 0.20 2.03 (0.16)
Social Support 85.9 (28.5) -2.1 (20.9) -0.1 (23.5) -0.07 -0.10 -0.09 0.08 (0.78)
Cognitions 75.4 (16.5) -3.9 (22.6) -2.1 (13.3) -0.24
d -0.17 -0.29 0.12 (0.73)
Communication 77.9 (23.2) -4.2 (17.7) -5.7 (20.1) -0.18 -0.23 -0.20 0.07 (0.79)
Bodily Discomfort 64.6 (24.2) -2.1 (18.6) 1.7 (20.9) -0.09 -0.11 -0.10 0.38 (0.54)
Total score 74.9 (16.4) -4.7 (11.5) 1.3 (13.3) -0.29
d -0.41 -0.35 2.38 (0.13)
a Declined group declined two or more categories from baseline to follow-up (n = 16); Unchanged group had change of one point or less from
baseline to follow-up (n = 35). All the scales scored on a 0 (worst) to 100 (best) possible range, except for the SF-36 PCS and MCS, which are
T-scores (mean = 50, SD = 10) calculated against a reference population
b Large effect size (effect size between 0.20 and 0.49)
c Medium effect size (effect size between 0.50 and 0.79)
d Small effect size (effect size greater than or equal to 0.80)
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123medium ES, the ADL and Social Support scales had a
small ES, and the other ﬁve PDQ-39 scales did not
detect any change. The three PDQUALIF scales that had
less than adequate internal consistency reliability in our
study also did not perform well in the original study
introducing the PDQUALIF (in the original study, a
fourth scale Urinary Function also had Cronbach’s alpha
below 0.7) [11]. Using Hoehn and Yahr stage as a cri-
terion variable for their relative validity analysis, they
found that the F-statistic for the overall PDQUALIF
(10.8) was only a bit higher than the SF-36 PCS (9.1)
though considerably better than the SF-36 MCS (1.9).
The poor performance of the SF-36 MCS is likely due to
Hoehn and Yahr’s emphasis on balance and mobility.
When we used the PHQ-9 as a criterion variable in our
study, the SF-36 MCS outperformed overall scores of the
two PD-targeted HRQOL measures, as would be antici-
pated given that depression is a stronger component of
mental health than physical health. Emphasis of some
criterion variables on certain aspects of HRQOL was
also observed in our study with respect to the PD day-to-
day activities criterion variable, for which relative
validity and responsiveness were stronger for physical
and social functioning scales of all the measures than
with scales tapping mental health.
The following limitations to our study should be
noted. We recruited a convenience sample of 96 PD
patients, and the portion of our analyses involving lon-
gitudinal data (responsiveness) was based on a subset of
the 60% of the enrolled sample for whom we were able
to collect follow-up data. Some of the sample sizes for
subgroups in the responsiveness analyses were relatively
small, and we recommend that our ﬁndings with regard
to responsiveness be conﬁrmed in samples having larger
subgroups who changed. Power to detect a difference
would have been increased with a larger sample size; for
example, we observed almost signiﬁcant F-statistic of
3.52 for the responsiveness of the SF-36 physical health
summary score in Table 6. With a larger sample size we
may have found this test statistic to be statistically
signiﬁcant.
There was a higher proportion of men than in the
general PD population because about half of this study’s
sample was recruited from a VA. Another potential
limitation is that criterion variables were all self-repor-
ted, and it would have been useful to also include a
clinical measure such as the motor UPDRS, an exami-
nation recorded by a trained clinician, or the Hoehn and
Yahr stage. While we administered all the measures
using the same modality at different points in time, data
regarding the adequacy of telephone administration of
the PDQUALIF is unknown.
The results of this study suggest that both generic and
disease-targeted measures contribute important information
about HRQOL. In the future, both generic and disease-
targeted items tapping the same domain could be included
together in an item bank and administered using computer
adaptive testing [34].
Conclusion
A comparison of the psychometric properties between a
generic and two PD-targeted HRQOL measures provides
evidence for superior or equivalent responsiveness of the
generic HRQOL measure over the PD-targeted HRQOL
measures. However, the PD-targeted measures account for
additional content beyond the generic HRQOL measure
alone. The empirical ﬁndings related to lack of superior
responsiveness of the PD-targeted measures relative to the
SF-36 may in part be explained by inadequate scaling of
the original PD-targeted measures.
The ﬁndings of this study provide support for use of a
combination of generic and disease-targeted HRQOL
measures in future research.
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Total Patients with
follow-up data
Patients without
follow-up data
Wilcoxon
P-value
N (%)
Mean (SD)
N = 96
N (%)
Mean (SD)
N = 58
N (%)
Mean (SD)
N = 38
Overall, during the last 6 months, how would you rate
the severity of your Parkinson’s disease symptoms?
No symptoms 1 (1.0) 1 (1.7) 0 (0.0) 0.13
Mild symptoms 39 (40.6) 27 (46.6) 12 (31.6)
Moderate symptoms 45 (46.9) 24 (41.4) 21 (55.3)
Severe symptoms 11 (11.5) 6 (10.3) 5 (13.2)
PHQ-9 categories for planning and monitoring treatment
May not need depression treatment (scores: 0–4) 37 (38.9) 25 (43.9) 12 (31.6) 0.11
Based on clinical judgment about treatment on
duration of symptoms and functional impairment (scores: 5–14)
47 (49.5) 28 (49.1) 19 (50.0)
Warrants treatment for depression using antidepressant,
psychotherapy, and/or a combination treatment approach
scores: 15–27)
11 (11.6) 4 (7.0) 7 (18.4)
Table 8 Relative validity of HRQOL scales by rating of Parkinson’s disease symptoms (N = 96)
a
Scale Rating of severity of Parkinson’s disease symptoms
No or mild symptoms
(n = 40)
Moderate symptoms
(n = 45)
Severe symptoms
(n = 11)
F-ratio
b Relative
validity
c
SF-36 v. 1.0 (range: 0–100, where 100 is best quality of life)
Physical Function 77.0
d 47.7
e 30.9
f 20.22 5.04
Role Limitations—Physical 51.3
d 12.2
e 11.4
e 20.23 5.04
Role Limitations—Emotional 90.0
d 68.2
d,e 60.6
e 4.01
c 1.00
Pain 72.8
d 60.4
d 39.6
e 8.38 2.09
Emotional Well-Being 76.5
d 66.8
d,e 57.1
e 6.81 1.70
Energy 56.9
d 42.6
e 29.6
f 9.17 2.29
General Health 60.6
d 49.6
d 34.1
e 7.98 1.99
Social Function 81.9
d 48.6
e 35.2
e 19.95 4.98
SF-36 composite scores (T-scores)
Physical Health (PCS) 42.5
d 32.5
e 26.1
f 21.47 5.35
Mental Health (MCS) 53.1
d 46.9
d,e 42.9
e 4.77 1.19
PDQUALIF (range: 0–100, where 100 is best quality of life)
Social/Role Function 69.5
d 42.5
e 30.6
e 22.55 5.62
Self-Image and Sexuality 75.5
d 52.1
e 36.8
f 24.42 6.09
Sleep 75.0
d 58.0
e 52.5
e 5.30 1.32
Outlook 71.6
d 55.8
d 42.5
e 12.44 3.10
Physical Function 79.4
d 65.0
e 64.0
e 9.56 2.38
Independence 89.4
d 76.1
d 52.5
e 6.00 1.50
Urinary Function 51.3
d 33.6
d,e 17.5
e 5.19 1.29
Total score 73.1
d 54.7
e 42.3
f 24.60 6.13
PDQ-39 (range: 0–100, where 100 is best quality of life)
Mobility 82.4
d 51.6
e 31.9
f 29.22 7.29
Activities of Daily Living 79.3
d 58.7
e 41.3
f 17.27 4.31
Emotional Well-Being 84.7
d 69.9
e 54.2
f 13.01 3.24
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Scale Rating of severity of Parkinson’s disease symptoms
No or mild symptoms
(n = 40)
Moderate symptoms
(n = 45)
Severe symptoms
(n = 11)
F-ratio
b Relative
validity
c
Stigma 84.5
d 69.4
d,e 59.7
e 5.21 1.30
Social Support 95.4
d 78.2
e 59.9
f 12.06 3.01
Cognitions 83.3
d 66.9
e 63.6
e 9.71 2.42
Communication 90.1
d 66.9
e 59.1
e 19.02 4.74
Bodily Discomfort 72.3
d 55.6
e 52.3
e 7.93 1.98
Total score 84.0
d 64.7
e 52.7
f 31.29 7.80
a All the scales scored on a 0 (worst) to 100 (best) possible range, except for the SF-36 PCS and MCS, which are T-scores (mean = 50,
SD = 10) calculated against a reference population
b One way between group ANOVAs of HRQOL scale and PD symptom severity
c Reference scale = SF-36 Role Limitations—Emotional (F-ratio = 4.01)
d, e, f Means within a row with different letters differ signiﬁcantly (P\0.05; Duncan multiple range)
Table 9 Relative validity of HRQOL scales by PHQ-9 scoring categories (N = 96)
a
Scale PHQ-9 scoring categories
Depression treatment
may not be needed
(n = 37)
Clinical judgment about treatment
on duration of symptoms and
functional impairments (n = 47)
Warrants treatment for
depression (n = 11)
F-ratio
b Relative
validity
c
SF-36 v. 1.0 (range: 0–100, where 100 is best quality of life)
Physical Function 73.7
d 49.8
e 44.6
e 8.88 1.55
Role Limitations—Physical 50.7
d 17.6
e 2.3
e 16.78 2.93
Role Limitations—Emotional 100.0
d 75.9
e 6.1
f 40.29 7.04
Pain 77.0
d 58.5
e 40.9
f 12.18 2.13
Emotional Well-Being 81.0
d 68.7
e 42.6
f 43.63 7.63
Energy 66.2
d 40.5
e 24.6
f 26.50 4.63
General Health 62.3
d 49.6
e 35.9
f 8.80 1.54
Social Function 84.1
d 52.4
e 25.0
f 26.88 4.70
SF-36 composite scores (T-scores)
Physical Health (PCS) 41.6
d 33.1
e 32.4
e 10.06 1.76
Mental Health (MCS) 56.8
d 48.4
e 28.3
f 51.97 9.09
PDQUALIF (range: 0–100, where 100 is best quality of life)
Social/Role Function 72.5
d 44.1
e 22.0
f 37.13 6.49
Self-Image and Sexuality 74.5
d 54.2
e 39.0
f 17.59 3.08
Sleep 82.7
d 57.3
e 34.9
f 21.97 3.84
Outlook 75.34
d 55.9
e 34.6
f 28.75 5.03
Physical Function 78.5
d 68.1
e 57.7
f 8.43 1.47
Independence 90.9
d 75.5
d 55.8
e 6.03 1.05
Urinary Function 53.4
d 32.5
e 21.6
e 5.72
c 1.00
Total score 75.4
d 55.4
e 37.9
f 41.04 7.18
PDQ-39 (range: 0–100, where 100 is best quality of life)
Mobility 82.0
d 52.1
e 40.0
e 20.11 3.52
Activities of Daily Living 78.8
d 60.6
e 40.9
f 14.71 2.57
Emotional Well-Being 89.3
d 69.8
e 43.2
f 38.00 6.64
Stigma 86.0
d 70.8
d 53.9
e 7.18 1.26
Social Support 94.8
d 79.4
e 63.6
f 8.60 1.50
Cognitions 82.8
d 70.6
e 51.1
f 13.99 2.45
Communication 88.1
d 71.5
e 53.0
f 13.92 2.43
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Scale PHQ-9 scoring categories
Depression treatment
may not be needed
(n = 37)
Clinical judgment about treatment
on duration of symptoms and
functional impairments (n = 47)
Warrants treatment for
depression (n = 11)
F-ratio
b Relative
validity
c
Bodily Discomfort 74.8
d 57.4
e 41.7
f 14.34 2.51
Total score 84.6
d 66.5
e 48.4
f 35.89 6.27
a All the scales scored on a 0 (worst) to 100 (best) possible range, except for the SF-36 PCS and MCS, which are T-scores (mean = 50,
SD = 10) calculated against a reference population
b One way between group ANOVAs of HRQOL scale and PHQ-9 scoring categories
c Reference scale = PDQUALIF—Urinary Function (F-ratio = 5.72)
d, e, f Means within a row with different letters differ signiﬁcantly (P\0.05; Duncan multiple range)
Table 10 Stepwise regression (N = 96)
Model 1: Independent variable = SF-36 scales Model 2: Independent variable = signiﬁcant SF-36 scales from Model 1
(P\0.10) ? PDQUALIF items ? PDQ-39 items
R
2; Adjusted R
2 Scales P value R
2; Adjusted R
2 Scales P value
Criterion variable #1: How PD affects on day-to-day basis Criterion variable #1: How PD affects on day-to-day basis
0.50; 0.48 Social Function 0.001 0.67; 0.65 Social Function
a 0.09
Physical Function 0.003 Physical Function
a 0.005
Role Limitations—Physical 0.01 Role Limitations—Physical
a 0.004
PDQUALIF items
Financial strain Self-image/sexuality 0.04
Adjust to change Social Role Function 0.003
Sleep with partner Sleep 0.03
PDQ-39 items
Getting around house Mobility 0.006
Memory Cognitions 0.002
Criterion variable #2: Quality of life rating Criterion variable #2: Quality of life rating
0.47; 0.45 Role Limitations—Physical 0.02 0.69; 0.65 Role Limitations—Physical
a 0.19
General Health 0.01 General Health
a 0.002
Role Limitations—Emotional 0.04 Role Limitations—Emotional
a 0.59
Emotional Well-Being 0.06 Emotional Well-Being
a 0.004
PDQUALIF items
Sexual ability Self-image/sexuality 0.005
Future Outlook \0.001
Ask for help 0.02
Independent hygiene Independence 0.02
PDQ-39 items
Conﬁned to the house Mobility 0.001
Isolated and lonely Emotional Well-Being 0.006
Concentration Cognitions 0.006
Criterion variable #3: Rating of severity of PD symptoms Criterion variable #3: Rating of severity of PD symptoms
0.42; 0.40 Physical Function 0.006 0.71; 0.67 Physical Function
a 0.10
Social Function 0.03 Social Function
a 0.93
General Health 0.07 General Health
a 0.24
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Model 1: Independent variable = SF-36 scales Model 2: Independent variable = signiﬁcant SF-36 scales from Model 1
(P\0.10) ? PDQUALIF items ? PDQ-39 items
R
2; Adjusted R
2 Scales P value R
2; Adjusted R
2 Scales P value
Role Limitations—Physical 0.07 Role Limitations—Physical
a 0.02
PDQUALIF items
Imbalance Social/Role Function 0.001
Usual share of work in home 0.02
Self-concept/image Self-Image/Sexuality 0.009
Sexual ability 0.005
PDQ-39 items
Memory Cognitions \0.001
Hallucinations 0.008
Criterion variable #4: PHQ-9 scoring categories Criterion variable #4: PHQ-9 scoring categories
0.65; 0.64 Emotional well being 0.008 0.81; 0.78 Emotional well being
a 0.51
Pain 0.009 Pain
a 0.02
Energy 0.001 Energy
a 0.03
Role Limitations—Emotional 0.007 Role Limitations—Emotional
a 0.003
PDQUALIF items
Financial strain Self-Image/Sexuality 0.002
Sleep maintenance Sleep 0.001
Outlook Outlook \0.001
PDQ-39 items
Close relationship Social Support 0.001
Concentration Cognitions 0.008
a Forced into Model 2 based on signiﬁcance in Model 1
Table 11 Multitrait scaling of PDQUALIF items (N = 96)
Social/Role
Function
Self-Image and
Sexuality
Sleep Outlook Physical
Function
Independence Urinary
Function
Social/Role Function
Work in home 0.72
a 0.53 0.46 0.48 0.54 0.66 0.26
Social life I 0.56
a 0.49 0.19 0.42 0.26 0.14 0.03
Imbalance 0.60
a 0.51 0.30 0.42 0.49 0.57 0.34
Social life II 0.79
a 0.69 0.39 0.60 0.45 0.31 0.21
Burden 0.60
a 0.58 0.38 0.58 0.42 0.33 0.27
Fatigue 0.61
a 0.52 0.52 0.52 0.43 0.35 0.28
Social isolation 0.80
a 0.66 0.39 0.57 0.47 0.34 0.24
Travel 0.32
a 0.17 0.25 0.20 0.44 0.28 0.07
Adjust to change 0.55
a 0.45 0.37 0.61 0.34 0.28 0.12
Self Image and Sexuality
Self concept 0.38 0.53
a -0.04 0.38 0.35 0.14 0.05
Sexual ability 0.35 0.33
a 0.23 0.18 0.25 0.33 0.44
Family relationship 0.63 0.62
a 0.33 0.61 0.48 0.18 0.23
Sexual desirability 0.65 0.67
a 0.28 0.67 0.44 0.32 0.21
Communication I 0.51 0.56
a 0.37 0.42 0.35 0.25 0.17
Communication II 0.50 0.56
a 0.33 0.34 0.30 0.29 0.24
Financial strain 0.37 0.48
a 0.19 0.26 0.36 0.27 0.15
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Social/Role
Function
Self-Image and
Sexuality
Sleep Outlook Physical
Function
Independence Urinary
Function
Sleep
Sleep initiation 0.53 0.38 0.63
a 0.46 0.38 0.33 0.41
Sleep maintenance 0.43 0.26 0.56
a 0.37 0.27 0.17 0.48
Sleep with partner 0.16 0.17 0.14
a 0.12 0.21 0.20 0.22
Outlook
Future 0.51 0.44 0.30 0.52
a 0.16 0.09 0.18
Maintain independence 0.13 0.03 0.15 -0.11
a 0.17 0.29 0.05
Ask for help 0.41 0.49 0.23 0.37
a 0.29 0.05 0.11
Outlook 0.68 0.53 0.42 0.66
a 0.37 0.28 0.21
Physical Function
Neuropathy 0.37 0.29 0.20 0.13 0.35
a 0.27 0.11
Dizziness 0.31 0.32 0.05 0.31 0.23
a 0.07 -0.06
Swallow 0.41 0.49 0.31 0.32 0.37
a 0.43 0.15
Driving 0.33 0.14 0.14 0.13 0.18
a 0.23 0.04
Constipation 0.31 0.34 0.41 0.25 0.22
a 0.39 0.50
Independence
Independent hygiene 0.51 0.39 0.28 0.23 0.49 0.73
a 0.29
Independent food prep 0.43 0.32 0.29 0.24 0.40 0.73
a 0.22
Urinary Function
Nocturia 0.20 0.29 0.47 0.18 0.18 0.20 0.80
a
Uro frequency 0.33 0.32 0.49 0.24 0.32 0.32 0.80
a
Bold values = highest item-scale correlation for a given item, unless the highest item-scale correlation is with the scale in which that item is
placed. Italics values = item-scale correlation is less than a half of standard error (0.05) below or is higher than the correlation of that item with
the scale in which it is placed
a Item’s original scale
Table 12 Multitrait scaling of PDQ-39 items (N = 96)
Mobility Activities of
Daily Living
Emotion
Well-Being
Stigma Social
Support
Cognitions Communication Bodily
Discomfort
Mobility
Leisure activities 0.65
a 0.58 0.54 0.37 0.51 0.49 0.49 0.42
Looking after home 0.79
a 0.63 0.36 0.28 0.22 0.36 0.46 0.56
Carry shopping bags 0.87
a 0.67 0.33 0.23 0.22 0.25 0.42 0.46
Walk half mile 0.83
a 0.64 0.30 0.20 0.33 0.28 0.37 0.46
Walk 100 yards 0.79
a 0.59 0.25 0.23 0.24 0.22 0.32 0.41
Getting around house 0.66
a 0.62 0.24 0.21 0.27 0.26 0.42 0.38
Getting around public 0.73
a 0.62 0.37 0.31 0.36 0.37 0.53 0.48
Accompanied when out 0.62
a 0.52 0.25 0.16 0.15 0.18 0.25 0.42
Worried about falling 0.70
a 0.56 0.36 0.30 0.28 0.39 0.42 0.46
Conﬁned to house 0.64
a 0.51 0.50 0.28 0.44 0.41 0.43 0.44
Activities of Daily Living
Washing 0.76 0.76
a 0.24 0.13 0.24 0.38 0.43 0.43
Dressing 0.75 0.84
a 0.25 0.19 0.25 0.41 0.39 0.48
Buttons and laces 0.64 0.74
a 0.22 0.16 0.24 0.44 0.32 0.42
Writing 0.46 0.62
a 0.26 0.17 0.22 0.39 0.50 0.33
Cutting food 0.63 0.85
a 0.31 0.26 0.27 0.48 0.53 0.49
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